Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017 - Yu, Jingjing; Petrie, Ichiko D.; Levy, René H.; Ragueneau-Majlessi, Isabelle (Drug metabolism and disposition, 2019)
Keywords: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antiviral agents; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Area Under Curve; Breast cancer; Clinical significance; Cytochrome P-450 CYP3A - metabolism; Cytochrome P-450 CYP3A Inhibitors - pharmacology; Cytochrome P-450 CYP3A Inhibitors - therapeutic use; Data processing; Drug Approval; Drug interaction; Drug Interactions; Drug Therapy, Combination - adverse effects; Drugs; Enzymes; FDA approval; Food; Inhibitors; Labels; Liver-Specific Organic Anion Transporter 1 - antagonists & inhibitors; Liver-Specific Organic Anion Transporter 1 - metabolism; Neoplasms - drug therapy; Oncology; Organic anion transporting polypeptide; Pharmacokinetics; Pharmacology; Proteins; Solute Carrier Organic Anion Transporter Family Member 1B3 - antagonists & inhibitors; Solute Carrier Organic Anion Transporter Family Member 1B3 - metabolism; Substrate inhibition; United States; United States Food and Drug Administration; Virus Diseases - drug therapy; United States; United States--US; BCRP; PGx; FDA; NTI; UGT; NME; DDI; PBPK; NDA; OATP; PXR; AUC; P450; PK